Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Huseyın Cem Onal"'
Autor:
Abdul Rahman Jazieh, Huseyin Cem Onal, Daniel Shao-Weng Tan, Ross A. Soo, Kumar Prabhash, Amit Kumar, Reto Huggenberger, Byoung Chul Cho
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Tyrosine kinase inhibitors (TKIs) are the standard of care for resectable and metastatic non-small-cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations (EGFRm). We describe the real-world practice of EGFRm
Externí odkaz:
https://doaj.org/article/346f0d01f55749cd9795ce7d7269daa2
Autor:
Huseyin Mertsoylu, Mehmet Artac, Celaletdin Camci, Nuriye Ozdemir, Mehmet Ali Nahit Sendur, Arzu Baygul, Bulent Karabulut, Huseyin Abali, Burce Goktas, Suayib Yalcin, Berna Oksuzoglu, Burcin Budakoglu, Faysal Dane, Fatma Buğdaycı Başal, Fatih Ozdener, Huseyın Cem Onal
Background: Trastuzumab prolonged the overall survival in patients with advanced gastric cancer with human epidermal growth factor receptor 2 (HER2) overexpression in combination with chemotherapy. In this phase II open-label prospective study, the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a44f3ebf6a13959f0762867ae06cc75f
https://avesis.gazi.edu.tr/publication/details/c0518f33-e4c6-4042-8712-e074abd00247/oai
https://avesis.gazi.edu.tr/publication/details/c0518f33-e4c6-4042-8712-e074abd00247/oai
Autor:
Amit Kumar, Kumar Prabhash, Huseyın Cem Onal, S. Robb, Byoung Chul Cho, R. Huggenberger, Abdul Rahman Jazieh, Ross A. Soo, Daniel Shao Weng Tan
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(10)
Stage III NSCLC is a heterogeneous disease requiring a multimodal management approach. We conducted a real-world, global study to characterize patients, treatment patterns, and their associated clinical outcomes for stage III NSCLC.KINDLE was a retro
Autor:
H. El Ashry, E. Kaytan Saglam, Rabab Gaafar, Abdul Rahman Jazieh, E. Dawoud, M. Alsayed, Y. Abdelkader, D. Alshorbagy, Huseyın Cem Onal, M. Nassar
Publikováno v:
Annals of Oncology. 32:S942-S943
Autor:
Kumar Prabhash, S. Robb, Byoung Chul Cho, Huseyın Cem Onal, Amit Kumar, Daniel Shao Weng Tan, R. Huggenberger, Abdul Rahman Jazieh, Ross A. Soo
Publikováno v:
Journal of Thoracic Oncology. 16:S110-S111
Autor:
S. Robb, Kumar Prabhash, R. Huggenberger, Huseyın Cem Onal, Abdul Rahman Jazieh, D. S. Weng Tan, C. Cho, Ross A. Soo, Amit Kumar
Publikováno v:
Annals of Oncology. 31:S1384
Autor:
Kumar Prabhash, Amit Kumar, S. Robb, D. S. Weng Tan, Abdul Rahman Jazieh, Byoung Chul Cho, Ross A. Soo, Huseyın Cem Onal, R. Huggenberger
Publikováno v:
Annals of Oncology. 31:S1384
Autor:
Huseyın Cem Onal, R. Huggenberger, S. Robb, Abdul Rahman Jazieh, Daniel Shao-Weng Tan, Ross A. Soo, Byoung Chul Cho, Amit Kumar, Kumar Prabhash
Publikováno v:
Journal of Clinical Oncology. 38:9043-9043
9043 Background: Stage III NSCLC is a heterogeneous disease requiring a multimodality approach. We conducted a global study to characterise the patients (pts), treatment patterns and their associated outcomes for this disease in a real-world setting
Autor:
Berrin Pehlivan, Huseyin Mertsoylu, Bulent Erdogan, Mehmet Nur Altinors, Erkan Topkan, Melih Cekinmez, Orhan Sen, Feyzi Birol Sarica, Kadir Tufan, Huseyın Cem Onal
Publikováno v:
Asian Journal of Neurosurgery
Background: Anaplastic astrocytoma (AA; WHO grade-III) patients determination of prognostic factors helps generating multimodal therapy protocols. For this purpose, in the Baskent University, Adana Medical Research Center, specific characteristics of